FDA Guidance and Notices, October 2025: Draft Guidance on QMS Information in Premarket Reviews and a Warning on RF Microneedling
October 2025 was a quiet month, but one draft deserves early attention from anyone preparing a premarket submission: on October 27, FDA released draft guidance on the quality management system (QMS) information it asks for in certain premarket submission reviews. A draft on performance testing and labeling for menstrual products followed the next day.
On October 15, a safety communication warned of burns, scarring, nerve damage and other complications reported after radiofrequency (RF) microneedling for dermatologic and aesthetic purposes. On the procedural side, eSTAR (the electronic Submission Template And Resource) became required for De Novo requests on October 1, with limited exceptions.
Final guidance
- Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments (October 22): Covers how to select, develop or modify clinical outcome assessments that are fit for purpose. Part of the Patient-Focused Drug Development series, it also appears in FDA's list of device program guidance.
Draft guidance
- Quality Management System Information for Certain Premarket Submission Reviews (October 27): Applies to certain premarket submission reviews and describes the quality management system information FDA asks for in them.
- Menstrual Products - Performance Testing and Labeling Recommendations (October 28): Recommendations on performance testing and labeling for menstrual products.
Safety communications and other updates
- Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication (October 15): FDA cites reports of burns, scarring, fat loss and nerve damage after dermatologic and aesthetic use. It advises against home use, says procedures should be done by trained health care providers, and asks that problems be reported.
Also this month
- October 1: eSTAR became mandatory for De Novo requests, with limited exceptions. The underlying final guidance dates from 2024.
Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles